GenSight Biologics Appoints Mohamed Genead as Chief Medical Officer
|Paris, France, May 3rd, 2017, 8:00am CET – GenSight Biologics S.A. (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, announced it has appointed Mohamed Genead, M.D., as Chief Medical Officer, effective May 1, 2017. Dr. Genead brings more than 15 years of experience to the role, including his most recent role as Vice President & Global Therapeutic Area Head for Ophthalmology/Retina Gene Therapy at Biogen.
Please find the full PDF press release attached. gensight_biologics_pr_genead_appointment_20170503